Immunodominant sites of human T cell lymphotropic virus type 1 envelope protein for murine helper T cells.
HTLV-I (human T cell lymphotropic virus type 1) is the retrovirus causally related to adult T cell leukemia/lymphoma and is also associated with a neurological disorder, tropical spastic paraparesis, or HTLV-I-associated myelopathy. The development of these two different diseases among HTLV-I-infected individuals may depend in part on differences in their T cell immunity associated with a difference of HLA phenotype. Peptides corresponding to 17 sites in the HTLV-I envelope protein were tested for their antigenicity for lymph node cells from B10.BR, B10.D2, B10.A(5R), and B10.HTT congenic mice, representing four independent MHC haplotypes, immunized with the native envelope protein. Ten of the 17 tested sites were predicted to be amphipathic alpha-helical sites and all of them were found to be antigenic for at least one of the four MHC congenic strains of mice. Three of the 17 sites were amphipathic 3(10)-helical sites and four sites were predicted to be non-helical sites: none of the 3(10)-helical sites were antigenic and only one of four non-predicted sites was found to be immunodominant. Furthermore, three potent immunodominant peptides, V1E1 (342-363), V1E8/SP4a (191-209), and V1E10 (141-156) were also shown to be immunogenic; i.e., these peptides could be used to immunize mice to elicit proliferative responses of lymph node cells to the native HTLV-I envelope protein. Furthermore, these three peptides were able to prime animals for an enhanced antibody response to the native protein. Because this priming followed the same Ir gene control as the proliferative response, it probably reflects the ability of these peptides to prime helper T cells. The localization of immunodominant sites in HTLV-I envelope protein in mice may be useful for finding antigenic and immunogenic sites in humans, for developing a peptide vaccine for the virus, and possibly for aiding in prognosis for the development of different disease manifestations of HTLV-I infection.
Kurata
A
A
Molecular Immunogenetics and Vaccine Research Section, National Cancer Institute, Bethesda, MD 20892.
Palker
T J
TJ
Streilein
R D
RD
Scearce
R M
RM
Haynes
B F
BF
Berzofsky
J A
JA
D000465:Algorithms; D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis; D015486:HTLV-I Antigens / Q000008:administration & dosage / Q000032:analysis* / Q000276:immunology; D006801:Humans; D051379:Mice; D010455:Peptides / Q000276:immunology; D011487:Protein Conformation; D012191:Retroviridae Proteins / Q000008:administration & dosage / Q000032:analysis* / Q000276:immunology; D013601:T-Lymphocytes / Q000032:analysis*; D006377:T-Lymphocytes, Helper-Inducer / Q000276:immunology; D014759:Viral Envelope Proteins / Q000008:administration & dosage / Q000032:analysis* / Q000276:immunology
D000914:Antibodies, Viral; D015486:HTLV-I Antigens; D010455:Peptides; D012191:Retroviridae Proteins; D014759:Viral Envelope Proteins